New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
18:05 EDTMNOVMedicNova announces publication of positive phase 2 clinical results
MediciNova announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma. The publication reports on two Phase 2a clinical trials conducted by MediciNova, MN-221-CL-004 and MN-221-CL-005, which assessed the safety, tolerability, and FEV1 improvements in mild-moderate and moderate-to-severe asthmatics, respectively. MN-221 is designed to treat acute exacerbations via intravenous infusion, bypassing constricted airways to deliver the drug directly to the lungs. Preclinical studies showed MN-221 to have a high affinity for the beta(2)-adrenergic receptor, found primarily in the lungs, and a much lower affinity for the beta(1)-adrenergic receptor found primarily in cardiac tissue. These studies showed no worrisome increase in heart rate when MN-221 was administered.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
19:01 EDTMNOVMediciNova announces completion of enrollment in MN-166 clinical trial
MediciNova announced that the clinical trial of MN-166 in alcohol dependence has completed enrollment of 24 subjects. Yuichi Iwaki, MD, PhD, president and CEO of MediciNova, commented, "We are pleased that enrollment is now completed in our first study of MN-166 in alcohol dependence. We look forward to the final results of the study."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use